Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endocare delisted from Nasdaq:

This article was originally published in Clinica

Executive Summary

Urology diagnostic and device firm Endocare has been delisted from the Nasdaq stock market. Trading in the Irvine, California company's shares had been suspended since December 12. It had failed to provide financial reports, and the situation was exacerbated by its auditor admitting a lack of faith in senior management and the sacking of the chief financial officer (see Clinica No 1039, p 8). Endocare plans to appeal the delisting order, but there is no stay on the decision and trading on the OTC Bulletin Board is also banned because the company has not provided required filings to the Securities and Exchange Commission.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060742

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel